Emergent BioSolutions stock rises 3.91 percent with USD 368.1 million value

Published on 10/15/2026 at 22:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are set for November 2, 2026. Emergent BioSolutions stock costs EUR 6.43 on October 15, 2026, up 3.91 percent on the NYSE.

Analyst target and reporting date

HC Wainwright set a USD 10.00 target on September 9, 2026.
Emergent BioSolutions will discuss third-quarter results on November 2, 2026.
Emergent BioSolutions stock costs EUR 6.43 at Lang & Schwarz on October 15, 2026 at 10:14 p.m. CEST, up 3.91 percent on the NYSE versus the prior close.
Emergent BioSolutions had a USD 368.1 million market capitalization on October 15, 2026.

EBS, US29089Q1058, Illustration mit AI erstellt.

HC Wainwright issued a USD 10.00 price target for Emergent BioSolutions on September 9, 2026, according to MarketBeat. Against the USD 7.18 last price on the NYSE, the target is 39.28 percent higher. Emergent BioSolutions had a market capitalization of USD 368.1 million on October 15, 2026. Its stock was up 3.91 percent on the NYSE versus the prior close of October 14, 2026. At Lang & Schwarz, it was trading at EUR 6.43 on October 15, 2026 at 10:14 p.m. CEST.

Results date is November 2

Emergent BioSolutions will discuss its third-quarter 2026 results on November 2, 2026, at 5:00 p.m. Eastern time. The date was announced in a release carried by Business Wire. For investors, that date is the next clear checkpoint after the company reported second-quarter revenue of USD 234.30 million in August 2026.

Price position and range

The NYSE price of USD 7.18 stood 48.93 percent below the 52-week high of USD 14.06 and 64.68 percent above the low of USD 4.36 on October 15, 2026. Trading volume reached 621,848 shares, below the average volume of 1,157,564 shares. The current price therefore sits closer to the yearly low than the high, while the daily move was positive.

Valuation and dates

Emergent BioSolutions carried a trailing P/E ratio of minus 2.02 on October 15, 2026, and its dividend yield was 0.00 percent. The company operates in specialty pharmaceuticals and develops vaccines, therapeutics and other medical countermeasures for public health threats. The USD 10.00 analyst target from September 9, 2026 gives the stock a concrete valuation reference in its home currency.

Comparison with peers

EBS (NYSE, USD): plus 3.91 percent, P/E minus 2.02, market capitalization USD 368.1 million

SIGA Technologies (NASDAQ, USD): plus 2.90 percent, P/E minus 73.17, market capitalization USD 229.2 million

Vaxart (NASDAQ, USD): plus 2.51 percent, P/E 3.13, market capitalization USD 113.9 million

Trading closes at Lang & Schwarz

The euro quotation stood at EUR 6.43 at Lang & Schwarz on October 15, 2026 at 10:14 p.m. CEST. The home-market move was plus 3.91 percent on the NYSE versus the prior close of October 14, 2026. The further course of trading is shown by the continuously updated real-time quote of Emergent BioSolutions stock.